Prevalence, Characteristics, and Prognostic Significance of HFE Gene Mutations in Type 2 Diabetes
The Fremantle Diabetes Study
- Timothy M.E. Davis, FRACP1,
- John Beilby, PHD2,
- Wendy A. Davis, PHD1,
- John K. Olynyk, FRACP1,
- Gary P. Jeffrey, FRACP3,
- Enrico Rossi, PHD2,
- Conchita Boyder, MSC2 and
- David G. Bruce, FRACP1
- 1School of Medicine and Pharmacology, Fremantle Hospital, University of Western Australia, Fremantle, Australia
- 2Department of Clinical Biochemistry, PathWest, and the School of Surgery and Pathology, University of Western Australia, Perth, Australia
- 3School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, University of Western Australia, Perth, Australia
- Corresponding author: Professor T.M.E. Davis, tdavis{at}cyllene.uwa.edu.au
Abstract
OBJECTIVE—To examine the relationship between iron status, hereditary hemochromatosis (HFE) gene mutations, and clinical features and outcomes of type 2 diabetes in a well-characterized representative sample of community-based patients.
RESEARCH DESIGN AND METHODS—HFE genotype data were available for 1,245 type 2 diabetic patients from the longitudinal observational Fremantle Diabetes Study (FDS), representing 96.2% of the total FDS type 2 diabetes cohort. Data were collected at recruitment between 1993 and 1996 and annually until the end of June 2001. Hospitalization and mortality data were available until the end of June 2006. The presence of the C282Y HFE mutation was determined in all subjects and H63D in C282Y heterozygotes. Fasting serum iron, transferrin, and ferritin were measured in all C282Y homozygotes and C282Y/H63D heterozygotes and in 286 randomly selected wild-type subjects. Multiple logistic regression analysis was performed to determine independent baseline associates of prevalent complications (myocardial infarction, cerebrovascular disease, retinopathy, neuropathy, and nephropathy), as was Cox proportional hazards modeling to determine predictors of incident complications and mortality.
RESULTS—Although there were expected positive associations between HFE gene mutations and serum iron and transferrin saturation, there were no independent positive associations between HFE gene status and either microvascular or macrovascular complications in cross-sectional and longitudinal analyses. HFE gene status did not independently predict cardiac or all-cause mortality. Measures of iron metabolism including serum ferritin were not associated with combined microvascular or macrovascular end points.
CONCLUSIONS—Directed screening for iron overload and/or HFE mutations appears unwarranted in patients with type 2 diabetes.
Footnotes
-
Published ahead of print at http://care.diabetesjournals.org on 19 June 2008.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
-
- Accepted June 7, 2008.
- Received February 1, 2008.
- DIABETES CARE
